Sunday, November 10, 2024

United We Cure: Accelerating Cancer Research in San Diego

Share

Curebound unites San Diego’s top institutions in a collaborative effort to accelerate cancer research into cures. Founded upon a deeply held belief that cures are possible, Curebound believes that the next decade will be critical to the development of sophisticated, individualized cancer treatment and the largest opportunity ever seen to advance the way we treat, and ultimately cure cancer.

In 2021, two highly respected local cancer organizations, Padres Pedal the Cause and Immunotherapy Foundation, united to form Curebound – with an initial goal to raise and invest $100+ million into cancer research in San Diego. Over the last decade, these two organizations have collectively awarded over $20 million in funding for 80+ research grants that explore 20+ types of adult and pediatric cancers – including 6 pioneering clinical trials. To accelerate its impact, Curebound launched a Founder’s Fund campaign in 2021, which has since raised over $25 million in new commitments – bringing cumulative commitments since 2013 to over $50 million.

With 1 in 2 men and 1 in 3 women expected to be diagnosed with cancer, Curebound’s mission is to mobilize San Diego to accelerate cures for cancer in our lifetime.

Why San Diego?
San Diego is recognized as one of the largest and fastest growing life-science communities in the country and uniquely positioned as a global center for cancer research, innovation and care. The city is home to three NCI-designated cancer centers, internationally recognized biotech research institutions, top clinical care hospitals and nearly 1000 life-science companies. Headquartered amongst this powerful scientific hub, Curebound is the catalyst to bring these resources together to drive the work faster and further – to expedite discovery and improve the lives of patients today.

World Class Collaboration
Curebound’s cutting-edge collaborative model assembles the best scientists from San Diego’s leading research organizations including Moores Cancer Center, Salk Institute, Rady Children’s Hospital, Sanford Burnham Prebys, La Jolla Institute for Immunology and Scripps Research. Guided by a world-class Scientific Advisory Board, Curebound will award its next wave of cancer research grants beginning in December 2022. The first Cure Prize, a highly anticipated multi-million grant award for innovative, ground-breaking ideas intended to change the course of cancer research and care in San Diego will be awarded in early 2023. “We believe that best ideas happen when the right people work together,” added Anne Marbarger, CEO

Concert for Cures
Curebound’s annual events aim to bring all of San Diego’s diverse communities together in a shared effort to find a cure. Building on its flagship event, Padres Pedal the Cause to be held March 18, 2023, this fall Curebound will launch a new community celebration with its inaugural benefit concert at the beautiful Rady-Jacobs Shell. Mark your calendars for November 4, 2022 for exciting headliner information and details.

To learn more about Curebound and how you can get involved, visit www.curebound.org.

Danitza Villanueva
Danitza Villanueva
Danitza Villanueva was born in San Diego but spent her youth with her family in Tijuana and grew up on both sides of the border. She has transferred her unique insight of cross-border culture, trends and philanthropy to her business and community interests. Danitza is the first woman from her family to graduate from college. She has two degrees, one from Fashion Institute of Design and Merchandising in Fashion Marketing, and a second from San Diego Christian College in Communications. After starting GB Magazine with Esteban Villanueva in 2007, she has gone on to win awards and recognition from the community for her support of helping raise millions of dollars for non-profit organizations. Currently she resides in East County in San Diego where she and her husband Esteban run DAESVI Publishing, home to GB Magazine, among several other publications.

Read more

Latest